However, tumor location (P=0.2786), microsatellite status (P=0.1349), mutations in TP53 (P=0.1616), KRAS (P=0.6318), EGFR (P=0.7969), PIK3CA (P=0.6535) and tumor mutation burden (TMB, P=0.6922) did not show significant associations with PFS in this cohort. This evidence concerns the gene KRAS and neoplasm.